JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Literature Review to Understand the Burden and Current Non-surgical Management of Moderate-Severe Pain Associated with Knee Osteoarthritis

  • 0Rheumatology Department, Teknon Medical Center, Quirónsalud Group, Sarrià-Sant Gervasi, Carrer de La Marquesa de Vilallonga, 12, 08017, Barcelona, Spain. francisco.cdominguez@quironsalud.es.
Rheumatology and Therapy +

|

October 30, 2024

|

October 30, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Moderate-to-severe knee osteoarthritis (KOA) significantly impacts quality of life and incurs high costs. Current non-surgical treatments are often used despite lacking evidence-based recommendations, highlighting a need for better pain management options.

Area Of Science

  • Orthopedics
  • Rheumatology
  • Health Economics

Background

  • Knee osteoarthritis (KOA) with moderate-to-severe pain presents a significant burden on patients and healthcare systems.
  • Understanding the humanistic and economic impact is crucial for effective management strategies.

Purpose Of The Study

  • To review the humanistic burden, economic costs, and current guideline recommendations for non-surgical management of moderate-to-severe knee osteoarthritis (KOA).

Main Methods

  • A comprehensive literature search of Medline, Embase, EconLit, and Cochrane databases (2018-April 2023) was conducted.
  • Grey literature and reference lists were hand-searched, alongside identification of international treatment guidelines.

Main Results

  • 106 publications and 37 guidelines were reviewed, revealing a substantial humanistic and economic burden for patients with moderate-to-severe KOA.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) and intra-articular (IA) injections were common, yet guidelines often limit NSAID use and rarely recommend IA hyaluronic acid (HA) or opioids.
  • Guidelines lack specificity for moderate-to-severe pain and different KOA phenotypes.

Conclusions

  • Moderate-to-severe KOA imposes considerable humanistic and economic costs, with treatments frequently used off-label.
  • There is a critical need for novel therapeutic options to improve pain relief, enhance quality of life (QoL), and potentially postpone surgery.

Keywords: